(Q37809150)

23 August 2017

title

Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade (English)

1 reference

23 August 2017

Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade (English)

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

25 August 2024

0 references

Peter Boasberg

1

1 reference

23 August 2017

Omid Hamid

2

1 reference

23 August 2017

Steven O'Day

3

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21074058

25 August 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0093775410001582?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

https://api.elsevier.com/content/article/PII:S0093775410001582?httpAccept=text/plain

25 August 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

25 August 2024

1 reference

23 August 2017

volume

37

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

440-449

1 reference

CTLA-4 can function as a negative regulator of T cell activation

23 August 2017

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/1074-7613(94)90071-X

The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.8523

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.8525

Functions of Anti-MAGE T-Cells Induced in Melanoma Patients under Different Vaccination Modalities

2

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

25 August 2024

3

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

25 August 2024

4

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

25 August 2024

6

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

25 August 2024

7

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

25 August 2024

9

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

T-cell regulation by CD28 and CTLA-4.

25 August 2024

10

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

A cell culture model for T lymphocyte clonal anergy

25 August 2024

11

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

25 August 2024

14

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

CTLA-4 ligation blocks CD28-dependent T cell activation

25 August 2024

15

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

25 August 2024

16

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

CTLA-4 regulates cell cycle progression during a primary immune response.

25 August 2024

18

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

25 August 2024

19

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Enhancement of antitumor immunity by CTLA-4 blockade

25 August 2024

20

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

25 August 2024

21

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

25 August 2024

22

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

25 August 2024

23

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

25 August 2024

24

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

25 August 2024

26

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

25 August 2024

27

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Reversal of the TCR stop signal by CTLA-4

25 August 2024

28

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

25 August 2024

32

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Phase I/II study of ipilimumab for patients with metastatic melanoma

25 August 2024

33

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

25 August 2024

34

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

25 August 2024

35

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

25 August 2024

36

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

25 August 2024

37

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

25 August 2024

42

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

The treatment of brain metastases from malignant melanoma

25 August 2024

44

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

25 August 2024

45

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Complete regression of a previously untreated melanoma brain metastasis with ipilimumab

25 August 2024

47

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

25 August 2024

50

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells

25 August 2024

51

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

25 August 2024

53

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma

25 August 2024

54

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

25 August 2024

55

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

25 August 2024

56

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

25 August 2024

57

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

25 August 2024

58

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Anti-CTLA4 antibody-induced lupus nephritis

25 August 2024

59

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Autoimmune inflammatory myopathy after treatment with ipilimumab

25 August 2024

60

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

25 August 2024

62

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

25 August 2024

63

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells

25 August 2024

65

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody

25 August 2024

66

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

25 August 2024

67

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient

25 August 2024

68

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.004

25 August 2024

Identifiers

1 reference

23 August 2017

1 reference